Frontotemporal Dementia (FTLD) is a progressive neurodegenerative disease affecting behavior and language. With an early onset, its clinical presentation is highly heterogeneous and though its neuropathology, once thought mainly to be a tauopathy, has become increasingly complex. Relative to other dementias, FTLD has been considered a disorder difficult to diagnose, recently been appreciated as a leading cause of dementia, mainly in patients before the age of 65 years, and is still confused with Alzheimer (AD in early stages), Parkinson or psychiatric pathology -of later apparition-, preventing from an early diagnosis We analyzed San Ignacio's Hospital Memory outpatients Clinic (Bogota, Colombia) Database including all patients assessed from 1997 to 2010, including all sociodemographic, functional, Lawton scale or Instrumental Activities of Daily Living (IADL)), clinical and neuropsychological assessments. Out of 1.730 subjects, 218 were FTLD cases: 51% men and 49% women. 40% are below 60 and just 7% were over 80 years old. As the term FTLD includes 3 clinical variants (behavioural (bvFTD), semantic dementia (SD) and primary progressive aphasia (PPA)), it is discussed whether Primary Progressive Apraxia (PpxA) is part of the spectrum. Studied population characteristics are described in number of cases: bvFTD: 172; PPA: 20; PpxA: 5; SD: 10. Less frequent are: Cortico-gangliobasal Degeneration: 4, FTD linked to chromosome 17: 3, and Supranuclear Progressive Paralysis: 4. It is highlighted that FTLD diagnosis has become more frequent in the recent years, ie: 3% in 1998, 5% in 2000, 7% in 2003, 12% in 2008 and 20% in 2010. As in clinical practice both FTLD and AD can affect the frontal area (DFT at early stages and DA at later stages) the diagnosis error is common. Therefore, interdisciplinary clinical group experience as that in Memory Clinics, has resulted in a diagnosis sensibility increase of this spectrum. Possible reasons are: it has been learned to identify FTLD earlier; patients consult sooner; better detection by group experience, or medical community identification. Results stress the need to recognize these patients with high accuracy during life in order to increase our understanding of such particularly devastating illness that compromises uniquely human functions while subjects are still productive.